Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15416209 | 0.89 | FPR2 (0.36) | SLC6A4SLC6A3SLC6A2NOS2FPR2 | |
| SCHEMBL15415955 | 0.81 | FPR2 (0.33) | SLC6A4SLC6A3SLC6A2FPR2SCN9A | |
| SCHEMBL15415695 | 0.81 | FFAR1 (0.47) | — | |
| SCHEMBL8983701 | 0.80 | SLC6A2 (0.46) | SLC6A4SLC6A3SLC6A2HTR2C | |
| SCHEMBL15414948 | 0.80 | FFAR1 (0.43) | NOS2 | |
| SCHEMBL3611689 | 0.77 | SLC6A2 (0.45) | SLC6A4SLC6A3SLC6A2HTR2C | |
| Hydrochloric Acid SCHEMBL10773342 | 0.77 | PLD1 (0.44) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL1851212 | 0.76 | HTR2C (0.40) | HTR2C | |
| SCHEMBL15415018 | 0.76 | SLC6A4 (0.39) | SLC6A4SLC6A3SLC6A2ADRB1HTR2C | |
| SCHEMBL15415103 | 0.74 | SLC6A2 (0.36) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475820-B2 | Substituted imidazo[1,2-a]pyrazines as TNF activity modulators | UCB BIOPHARMA SPRL (BE) | 2016-10-25 | — | — | US | disclosed |
| US-20150191482-A1 | Imidazopyrazine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2015-07-09 | — | — | US | disclosed |
| EP-2872511-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009296-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191482-A1 | Imidazopyrazine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | SLC6A4 3442/4885SLC6A3 4138/4885SLC6A2 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.